Business Context and Reporting Period
This Form 6-K filing covers the month of February 2012 for Prana Biotechnology Limited (ASX: PBT), a foreign private issuer headquartered in Parkville, Victoria, Australia. The filing serves as a notice under Section 708A(5) of the Corporations Act regarding a specific securities issuance.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a capital raise event.
- Securities Issued: 1,228,820 Ordinary Fully Paid Shares
- Issue Date: February 9, 2012
- Total Proceeds: AUD$ 217,819
- Regulatory Compliance: Issued without disclosure to investors under Part 6D.2 of the Corporations Act; compliance with Chapter 2M and Section 674 confirmed.
Material Changes
The primary material change is the increase in the company's share capital resulting from the issuance of 1,228,820 new ordinary shares. The company has applied to the ASX for quotation of these shares. No other material changes to operations or financial position are disclosed in this text.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a statutory notice confirming the issuance of shares and the company's compliance with relevant sections of the Corporations Act.
Investor Verification Checklist
- Verify the exact issue price per share (Total Proceeds / Number Issued) to confirm the valuation at issuance.
- Confirm the current trading status of the newly issued shares on the ASX following the application for quotation.
- Review the company's latest Form 20-F or annual report for context on how these proceeds impact overall liquidity and operational runway, as this 6-K does not provide that data.
- Note the discrepancy between the request metadata ("Alterity Therapeutics Ltd") and the filing content ("Prana Biotechnology Limited"); verify the correct entity name for investment records.